Last reviewed 2026-04-20 · How we verify

autologous tumor cells

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Infection
• Chills
• Fatigue
• Pneumonia
• Erectile dysfunction
• Headache
• Paraesthesia
• Pyrexia
• Arthralgia
• Nausea
• COVID-19
• Influenza like illness

Key clinical trials

• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (PHASE1)
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
• Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer (PHASE1)
• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
• Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE1, PHASE2)
• Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1, PHASE2)
• A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group (PHASE3)
• KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• autologous tumor cells CI brief — competitive landscape report
• autologous tumor cells updates RSS · CI watch RSS
• Dana-Farber Cancer Institute portfolio CI